Arcturus therapeutics and csl announce european medicines agency validates marketing authorization application for arct-154 vaccine to prevent covid-19

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, and csl (asx:csl), and its vaccine business, csl seqirus, one of the largest influenza vaccine providers in the world, announced today that the european medicines agency (ema) has validated the marketing authori.
ARCT Ratings Summary
ARCT Quant Ranking